xi's moments
Home | Asia Pacific

India's drugs controller approves 2 COVID-19 vaccines

Xinhua | Updated: 2021-01-03 15:26

Vials of AstraZeneca's COVISHIELD, coronavirus disease (COVID-19) vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov 30, 2020.[Photo/Agencies]

NEW DELHI - The Drugs Controller General of India (DCGI) on Sunday gave its approval to two vaccines for emergency use.

Addressing media, DCGI Dr. V.G. Somani said the permission was granted for "restricted use in emergency situation."

He said that the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) met on Jan 1 and Jan 2, making recommendations in respect of proposal for restricted emergency approval of COVID-19 virus vaccine of "Serum Institute of India (SII)" and "Bharat Biotech" as well as Phase 3 clinical trial of "Cadila Healthcare Limited."

The SII, situated in southwestern city of Pune, presented a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield) encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from AstraZeneca/Oxford University, said a DCGI statement.

"The Subject Expert Committee (SEC) has reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue," he told media.

Global Edition
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349